Ji-Wang Chern
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Ji-Wang Chern has a total of 35 co-authors. Here are the top co-authors by number of shared publications:
Chien-Shu Chen
Department of Pharmacy, Chia-Nan University of Pharmacy and Science, Tainan 717, Taiwan, and School of Pharmacy, College of Medicine, National Taiwan University, Taipei 100, Taiwan
3 shared publicationsGrace Shiahuy Chen
Department of Applied Chemistry, Providence University, Shalu 433, Taiwan, R.O.C.
3 shared publications- Tun-Cheng Chien
Department of Chemistry
2 shared publications Yen-Chywan Liaw
School of Pharmacy, College of Medicine, National Taiwan University, No. 1, Section 1, Jen-Ai Road, Taipei (100), Taiwan, Institute of Pharmacy, National Defense Medical Center, Taipei (100), Taiwan, Drug Development Division, Development Center for Biotechnology, Hsi-Chih Cheng, Taipei Hsien, Taiwan, Institute of Molecular Biology, Academia Sinica, Taipei, Taiwan, and Department of Pharmacy, Provincial Taoyuan Hospital, Taoyuan, Taiwan, Republic of China
2 shared publications- Aleksandrs Gutcaits
Latvian Institute of Organic Synthesis
1 shared publication - Andrew H.-J. Wang
University of Illinois at Urbana Champaign
1 shared publication
Latest Publications
- 1 March 2008
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 51 (6) , 1740-1746
Benzyl Ether-Linked Glucuronide Derivative of 10-Hydroxycamptothecin Designed for Selective Camptothecin-Based Anticancer Therapy
A β-glucuronidase-activated prodrug approach was applied to 10-hydroxycamptothecin, a Camptotheca alkaloid with promising antitumor activity but poor water solubility. We synthesized a glucuronide prodrug of 10-hydroxycamptothecin (7) in which glucuronic acid is connected via a self-immolative 3-nitrobenzyl ether linker to the 10-OH group of 10-hydroxycamptothecin. Compound 7 was 80 times more soluble than 10-hydroxycamptothecin in aqueous solution at pH 4.0 and was stable in human plasma. Prodrug 7 was 10- to 15-fold less toxic than the parent drug to four human tumor cell lines. In the presence of β-glucuronidase, prodrug 7 could be activated to elicit similar cytotoxicity to the parent drug in tumor cells. Enzyme kinetic studies showed that Escherichia coli β-glucuronidase had a quite low Km of 0.18 µM for compound 7 and exhibited 520 times higher catalytic efficiency for 7 than for 6 (a glucuronide prodrug of 9-aminocamptothecin). Molecular modeling studies predicted that compound 7 would have a higher binding affinity to human β-glucuronidase than compound 6. Prodrug 7 may be useful for selective cancer chemotherapy by a prodrug monotherapy (PMT) or antibody-directed enzyme prodrug therapy (ADEPT) strategy.
- 1 March 2008
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 51 (6) , 1740-1746
Benzyl Ether-Linked Glucuronide Derivative of 10-Hydroxycamptothecin Designed for Selective Camptothecin-Based Anticancer Therapy
A β-glucuronidase-activated prodrug approach was applied to 10-hydroxycamptothecin, a Camptotheca alkaloid with promising antitumor activity but poor water solubility. We synthesized a glucuronide prodrug of 10-hydroxycamptothecin (7) in which glucuronic acid is connected via a self-immolative 3-nitrobenzyl ether linker to the 10-OH group of 10-hydroxycamptothecin. Compound 7 was 80 times more soluble than 10-hydroxycamptothecin in aqueous solution at pH 4.0 and was stable in human plasma. Prodrug 7 was 10- to 15-fold less toxic than the parent drug to four human tumor cell lines. In the presence of β-glucuronidase, prodrug 7 could be activated to elicit similar cytotoxicity to the parent drug in tumor cells. Enzyme kinetic studies showed that Escherichia coli β-glucuronidase had a quite low Km of 0.18 µM for compound 7 and exhibited 520 times higher catalytic efficiency for 7 than for 6 (a glucuronide prodrug of 9-aminocamptothecin). Molecular modeling studies predicted that compound 7 would have a higher binding affinity to human β-glucuronidase than compound 6. Prodrug 7 may be useful for selective cancer chemotherapy by a prodrug monotherapy (PMT) or antibody-directed enzyme prodrug therapy (ADEPT) strategy.
- 1 December 2007
- Published by Wiley in Journal of the Chinese Chemical Society
- Vol. 54 (6) , 1387-1394
Physical Properties of 8‐Substituted 5,7‐Dichloro‐2‐Styrylquinolines as Potential Light Emitting Materials
- 1 December 2007
- Published by Wiley in Journal of the Chinese Chemical Society
- Vol. 54 (6) , 1387-1394
Physical Properties of 8‐Substituted 5,7‐Dichloro‐2‐Styrylquinolines as Potential Light Emitting Materials
- 1 December 2005
- Published by Wiley in Journal of the Chinese Chemical Society
- Vol. 52 (6) , 1237-1244
Nucleosides XIII. Facile Synthesis of 4-Amino-1-(2-deoxy-β-D-ribofuranosyl)quinazolin-2-one as a 2′-Deoxycytidine Analog for Oligonucleotide Synthesis
- 1 December 2005
- Published by Wiley in Journal of the Chinese Chemical Society
- Vol. 52 (6) , 1237-1244
Nucleosides XIII. Facile Synthesis of 4-Amino-1-(2-deoxy-β-D-ribofuranosyl)quinazolin-2-one as a 2′-Deoxycytidine Analog for Oligonucleotide Synthesis
- 1 December 2004
- Published by Wiley in Journal of the Chinese Chemical Society
- Vol. 51 (6) , 1401-1406
Nucleosides XII.1Synthesis of 5-Modified Isoguanosines and Reinvestigation of 5′-Deoxy-N3,5′-cycloisoguanosine
- 1 December 2004
- Published by Wiley in Journal of the Chinese Chemical Society
- Vol. 51 (6) , 1401-1406
Nucleosides XII.1Synthesis of 5-Modified Isoguanosines and Reinvestigation of 5′-Deoxy-N3,5′-cycloisoguanosine
- 14 February 2003
- Published by American Chemical Society (ACS) in The Journal of Organic Chemistry
- Vol. 68 (6) , 2502-2505
Studies on Quinazolines. 11. Intramolecular Imidate-Amide Rearrangement of 2-Substituted 4-(ω-Chloroalkoxy)quinazoline Derivatives. 1,3 -O → N Shift of Chloroalkyl Groups via Cyclic 1,3-Azaoxonium Intermediates
The ω-chloroalkylation of 2-substituted quinazolin-4(3H)-one derivatives 1 and 2 with Br-(CH2)n-Cl (n = 2−4) and the intramolecular imidate-amide rearrangement of the alkylated products are described. At room temperature, the 2-phenyl substituent promoted O-alkylation, whereas the less steric 2-benzyl group led to a higher ratio of N-alkylation. The investigation of the O-alkylated products, 4-ω-chloroalkoxyquinazolines, revealed that the migration of ω-chloroethyl and ω-chloropropyl groups from oxygen to nitrogen should be intramolecular via five- and six-membered cyclic 1,3-azaoxonium intermediates, respectively. Competition between rearrangement and nucleophilic substitution results in the formation of 7a,b and 8a,b from the nucleophilic substitution of 4a,b and 6a,b, respectively.
- 14 February 2003
- Published by American Chemical Society (ACS) in The Journal of Organic Chemistry
- Vol. 68 (6) , 2502-2505
Studies on Quinazolines. 11. Intramolecular Imidate-Amide Rearrangement of 2-Substituted 4-(ω-Chloroalkoxy)quinazoline Derivatives. 1,3 -O → N Shift of Chloroalkyl Groups via Cyclic 1,3-Azaoxonium Intermediates
The ω-chloroalkylation of 2-substituted quinazolin-4(3H)-one derivatives 1 and 2 with Br-(CH2)n-Cl (n = 2−4) and the intramolecular imidate-amide rearrangement of the alkylated products are described. At room temperature, the 2-phenyl substituent promoted O-alkylation, whereas the less steric 2-benzyl group led to a higher ratio of N-alkylation. The investigation of the O-alkylated products, 4-ω-chloroalkoxyquinazolines, revealed that the migration of ω-chloroethyl and ω-chloropropyl groups from oxygen to nitrogen should be intramolecular via five- and six-membered cyclic 1,3-azaoxonium intermediates, respectively. Competition between rearrangement and nucleophilic substitution results in the formation of 7a,b and 8a,b from the nucleophilic substitution of 4a,b and 6a,b, respectively.
- 1 March 2000
- Published by Elsevier in Tetrahedron Letters
- Vol. 41 (13) , 2207-2210
A new route towards the synthesis of substituted naphthalenes via Friedel–Crafts acylation
- 1 March 2000
- Published by Elsevier in Tetrahedron Letters
- Vol. 41 (13) , 2207-2210
A new route towards the synthesis of substituted naphthalenes via Friedel–Crafts acylation
- 21 July 1998
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 41 (17) , 3128-3141
Studies on Quinazolines and 1,2,4-Benzothiadiazine 1,1-Dioxides. 8. Synthesis and Pharmacological Evaluation of Tricyclic Fused Quinazolines and 1,2,4-Benzothiadiazine 1,1-Dioxides as Potential α1-Adrenoceptor Antagonists
A series of 2-substituted methyl 2,3-dihydroimidazo[1,2-c]quinazolin-5(6H)-ones (4), 3-substituted methyl 2,3-dihydroimidazo[1,2-c]quinazolin-5(6H)-ones (5), 3-substituted methyl 2,3-dihydro-5H-thiazolo[2,3-b]quinazolin-5-ones (15a,b), 3-substituted methyl 2,3-dihydroimidazo[2,1-b]quinazolin-5(1H)-ones (16a,b), 3-substituted methyl 2,3-dihydro-1H-imidazo[1,2-b][1,2,4]benzothiadiazine 5,5-dioxides (33a,b), 2-substituted methyl imidazo[1,2-c]quinazolin-5(6H)-ones (42 − 45a,b), 3-substituted methyl imidazo[1,2-c]quinazolin-5(6H)-ones (50 − 53a,b), 3-substituted methyl 5H-thiazolo[2,3-b]quinazolin-5-ones (55 − 56a,b), and 3-substituted methyl 5-(methylthio)-2,3-dihydroimidazo[1,2-c]quinazoline (57) were synthesized as compound 1 conformational rigid congeners for pharmacological evaluation as potential α1-adrenoceptor antagonists. Compounds 4, 5, 33a,b, 44a,b, 45a,b, 52a,b, 53a,b, and 57 were found to possess high affinity for the α1-adrenoceptor. Compounds 5 and 57 were the most highly selective and potent α1 antagonists with Ki = 0.21 ± 0.02 and 0.90 ± 0.08 nM, respectively. The S-enantiomers of these two compounds (Ki = 0.13 ± 0.01 nM for (S)-(−)-5; Ki = 1.0 ± 0.2 nM for (S)-(+)-57) were 144−200-fold more potent than the R-enantiomers (Ki = 26 ± 8 nM for (R)-(+)-5; Ki = 144 ± 23 nM for (R)-(−)-57). Compound 4 showed 8-fold higher affinity to α1A-AR better than α1B-AR. These compounds possessed weak to no activity against the 5-HT1A receptor.
- 21 July 1998
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 41 (17) , 3128-3141
Studies on Quinazolines and 1,2,4-Benzothiadiazine 1,1-Dioxides. 8. Synthesis and Pharmacological Evaluation of Tricyclic Fused Quinazolines and 1,2,4-Benzothiadiazine 1,1-Dioxides as Potential α1-Adrenoceptor Antagonists
A series of 2-substituted methyl 2,3-dihydroimidazo[1,2-c]quinazolin-5(6H)-ones (4), 3-substituted methyl 2,3-dihydroimidazo[1,2-c]quinazolin-5(6H)-ones (5), 3-substituted methyl 2,3-dihydro-5H-thiazolo[2,3-b]quinazolin-5-ones (15a,b), 3-substituted methyl 2,3-dihydroimidazo[2,1-b]quinazolin-5(1H)-ones (16a,b), 3-substituted methyl 2,3-dihydro-1H-imidazo[1,2-b][1,2,4]benzothiadiazine 5,5-dioxides (33a,b), 2-substituted methyl imidazo[1,2-c]quinazolin-5(6H)-ones (42 − 45a,b), 3-substituted methyl imidazo[1,2-c]quinazolin-5(6H)-ones (50 − 53a,b), 3-substituted methyl 5H-thiazolo[2,3-b]quinazolin-5-ones (55 − 56a,b), and 3-substituted methyl 5-(methylthio)-2,3-dihydroimidazo[1,2-c]quinazoline (57) were synthesized as compound 1 conformational rigid congeners for pharmacological evaluation as potential α1-adrenoceptor antagonists. Compounds 4, 5, 33a,b, 44a,b, 45a,b, 52a,b, 53a,b, and 57 were found to possess high affinity for the α1-adrenoceptor. Compounds 5 and 57 were the most highly selective and potent α1 antagonists with Ki = 0.21 ± 0.02 and 0.90 ± 0.08 nM, respectively. The S-enantiomers of these two compounds (Ki = 0.13 ± 0.01 nM for (S)-(−)-5; Ki = 1.0 ± 0.2 nM for (S)-(+)-57) were 144−200-fold more potent than the R-enantiomers (Ki = 26 ± 8 nM for (R)-(+)-5; Ki = 144 ± 23 nM for (R)-(−)-57). Compound 4 showed 8-fold higher affinity to α1A-AR better than α1B-AR. These compounds possessed weak to no activity against the 5-HT1A receptor.
- 1 July 1997
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 40 (14) , 2276-2286
Synthesis and Cytotoxic Evaluation of Substituted Sulfonyl-N-hydroxyguanidine Derivatives as Potential Antitumor Agents
A series of sulfonyl-N-hydroxyguanidine derivatives was designed and synthesized for cytotoxic evaluation as potential anticancer agents on the basis of the lead compound LY-181984. Replacement of the ureido moiety of the lead compound with hydroxyguanidine provided a stable cytotoxic agent. The conformation of sulfonyl-N-hydroxyguanidine derivatives, such as N-(4-chlorophenyl)-N'-[(benzo[2,1,3]thiadiazol-4-yl)sulfonyl]-N"- hydroxyguanidine (4g), investigated utilizing HMBC NMR, theoretical calculations, and X-ray crystallography, indicated stacking of the two aromatic rings. The derivatives were evaluated for in vitro cytoxicity against five human tumor cell lines, including HepG2, TSGH 8302, COLO 205, KB, and MOLT-4. The cytotoxic activities of the derived compounds against the human tumor cell lines were equal to or greater than that of the lead compound. N-(4-Chlorophenyl)-N'-[[3,5-dichloro-4-(4-nitrophenoxy)phenyl]sulfonyl]- N"- hydroxyguanidine (4n) and N-(4-chlorophenyl)-N'-[[3,5-dichloro-4-(2-chloro-4-nitrophenoxy)phenyl] sulfonyl]-N"-hydroxyguanidine (4o) exhibited the greatest growth inhibition of solid tumor cell lines. Compound 4o was found to possess antitumor activity against murine K1735/M2 melanoma xenografts.
- 1 July 1997
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 40 (14) , 2276-2286
Synthesis and Cytotoxic Evaluation of Substituted Sulfonyl-N-hydroxyguanidine Derivatives as Potential Antitumor Agents
A series of sulfonyl-N-hydroxyguanidine derivatives was designed and synthesized for cytotoxic evaluation as potential anticancer agents on the basis of the lead compound LY-181984. Replacement of the ureido moiety of the lead compound with hydroxyguanidine provided a stable cytotoxic agent. The conformation of sulfonyl-N-hydroxyguanidine derivatives, such as N-(4-chlorophenyl)-N'-[(benzo[2,1,3]thiadiazol-4-yl)sulfonyl]-N"- hydroxyguanidine (4g), investigated utilizing HMBC NMR, theoretical calculations, and X-ray crystallography, indicated stacking of the two aromatic rings. The derivatives were evaluated for in vitro cytoxicity against five human tumor cell lines, including HepG2, TSGH 8302, COLO 205, KB, and MOLT-4. The cytotoxic activities of the derived compounds against the human tumor cell lines were equal to or greater than that of the lead compound. N-(4-Chlorophenyl)-N'-[[3,5-dichloro-4-(4-nitrophenoxy)phenyl]sulfonyl]- N"- hydroxyguanidine (4n) and N-(4-chlorophenyl)-N'-[[3,5-dichloro-4-(2-chloro-4-nitrophenoxy)phenyl] sulfonyl]-N"-hydroxyguanidine (4o) exhibited the greatest growth inhibition of solid tumor cell lines. Compound 4o was found to possess antitumor activity against murine K1735/M2 melanoma xenografts.
- 30 June 1996
- Published by Elsevier in Tetrahedron: Asymmetry
- Vol. 7 (6) , 1641-1648
Studies on quinazolines. 6. Asymmetric synthesis of (S)-(+)- and (R)-(−)-3-[[4-(2-methoxyphenyl)piperazin-1-yl]methyl]-5-methylthio-2,3-dihydroimidazo[1,2-c]quinazolines
- 30 June 1996
- Published by Elsevier in Tetrahedron: Asymmetry
- Vol. 7 (6) , 1641-1648
Studies on quinazolines. 6. Asymmetric synthesis of (S)-(+)- and (R)-(−)-3-[[4-(2-methoxyphenyl)piperazin-1-yl]methyl]-5-methylthio-2,3-dihydroimidazo[1,2-c]quinazolines